888-969-2592
Kalkine 0
countryflagCA

Avicanna Inc

Healthcare CA AVCN

0.245CAD
-0.005(2.00%)

Last update at 2025-05-08T13:47:00Z

Day Range

0.240.24
LowHigh

52 Week Range

0.200.60
LowHigh

Fundamentals

  • Previous Close 0.25
  • Market Cap29.93M
  • Volume7000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.30749M
  • Revenue TTM24.87M
  • Revenue Per Share TTM0.27
  • Gross Profit TTM 1.12M
  • Diluted EPS TTM-0.1

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.73529M -16.76077M -35.04930M -23.24643M -7.28940M
Minority interest - - 7.89M 7.49M 8.07M
Net income -17.21971M -16.77454M -32.86170M -22.21304M -7.09906M
Selling general administrative 9.61M 12.53M 15.82M 20.53M 7.56M
Selling and marketing expenses 0.38M 0.35M 0.43M 0.65M 0.25M
Gross profit 1.12M 2.83M -0.57012M 0.09M -
Reconciled depreciation 0.89M 0.89M 1.09M 0.92M 0.17M
Ebit -10.57903M -10.83312M -18.53365M -22.77124M -7.09906M
Ebitda -9.69169M -9.93913M -17.44666M -21.84772M -6.92636M
Depreciation and amortization 0.89M 0.89M 1.09M 0.92M 0.17M
Non operating income net other - - - - -
Operating income -10.57903M -10.83312M -18.53365M -22.77124M -8.32381M
Other operating expenses 14.46M 14.68M 20.56M 23.39M 8.44M
Interest expense 1.67M 0.74M 0.26M 0.05M 0.00000M
Tax provision 0.00000M 0.01M -2.18760M -1.03339M -
Interest income 1.51M 1.82M 3.05M 0.41M 0.15M
Net interest income -1.67184M -0.73806M -0.26311M 0.01M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.48M 0.01M -2.18760M -1.03339M -
Total revenue 4.05M 3.27M 1.57M 0.17M 0.12M
Total operating expenses 11.53M 14.25M 18.42M 23.32M 8.44M
Cost of revenue 2.93M 0.44M 2.14M 0.08M -
Total other income expense net -4.15626M -5.92766M -16.51565M -0.47519M 1.03M
Discontinued operations - - - - -
Net income from continuing ops -14.73529M -16.77454M -32.86170M -22.21304M -7.28940M
Net income applicable to common shares -14.73529M -16.77454M -32.86170M -21.07197M -7.09906M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 21.97M 17.62M 22.30M 30.16M 45.16M
Intangible assets 1.19M 0.17M 0.30M 0.50M 11.06M
Earning assets - - - - -
Other current assets 0.47M 0.48M 0.90M 1.32M 0.12M
Total liab 14.00M 14.16M 15.39M 16.25M 15.29M
Total stockholder equity -0.11250M -0.38356M 1.15M 6.02M 22.39M
Deferred long term liab - - - - -
Other current liab 1.39M 3.84M 3.66M 4.49M 3.32M
Common stock 81.03M 74.89M 66.24M 57.47M 46.03M
Capital stock 81.03M 74.89M 66.24M 57.47M 46.03M
Retained earnings -98.71476M -90.82924M -77.40747M -62.03624M -30.80044M
Other liab - 2.35M 2.78M 3.26M 5.52M
Good will 0.33M - - 0.00000M 3.21M
Other assets - - 0.00000M 0.56M 3.78M
Cash 0.48M 1.19M 0.03M 1.27M 0.44M
Cash and equivalents - - - - -
Total current liabilities 11.97M 11.41M 12.20M 12.82M 8.72M
Current deferred revenue - - - 4.34M -
Net debt 1.33M 2.02M 1.63M 0.67M 0.83M
Short term debt 1.71M 2.81M 1.25M 1.78M 0.22M
Short long term debt 1.56M 2.66M 1.09M 1.57M 3.32M
Short long term debt total 1.80M 3.21M 1.66M 1.94M 1.27M
Other stockholder equity - 18.52M 16.47M 12.70M 8.28M
Property plant equipment - 10.39M 14.47M 21.81M 23.16M
Total current assets 8.46M 7.06M 7.35M 6.77M 3.95M
Long term investments - 0.00000M 0.18M 0.52M 0.00007M
Net tangible assets - - 0.85M 5.52M 8.12M
Short term investments - - 0.00000M 1.25M -
Net receivables 2.97M 2.15M 2.34M 1.01M 1.20M
Long term debt - 0.18M 0.42M 0.00000M 0.72M
Inventory 4.54M 3.24M 4.09M 1.93M 1.60M
Accounts payable 8.87M 4.75M 7.29M 6.56M 5.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 17.58M -2.97086M -4.15939M -2.11300M -1.12452M
Additional paid in capital - - - - -
Common stock total equity - - - - 46.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 1.05M 3.78M
Deferred long term asset charges - - - - -
Non current assets total 13.51M 10.55M 14.95M 23.39M 41.21M
Capital lease obligations 0.25M 0.37M 0.16M 0.36M 0.56M
Long term debt total - 0.40M 0.42M 0.16M 1.05M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.81M 1.25M -1.25000M -7.48949M -7.04042M
Change to liabilities 0.00000M 0.81M 1.38M 3.72M 0.82M
Total cashflows from investing activities 0.81M 0.76M -2.70711M -7.48949M -7.04042M
Net borrowings - 0.88M 4.53M 3.61M 0.42M
Total cash from financing activities 9.90M 10.06M 17.39M 27.31M 10.92M
Change to operating activities - -0.01237M -1.16698M 0.04M 0.34M
Net income -14.73529M -16.77454M -32.86170M -22.21304M -7.09906M
Change in cash 1.16M -1.23573M 0.82M 0.37M -1.10725M
Begin period cash flow 0.03M 1.27M 0.44M 0.07M 1.18M
End period cash flow 1.19M 0.03M 1.27M 0.44M 0.07M
Total cash from operating activities -7.43537M -11.66302M -13.97045M -19.44962M -4.99079M
Issuance of capital stock 9.08M 9.09M 12.86M 0.00000M 5.66M
Depreciation 0.89M 0.89M 1.09M 0.92M 0.17M
Other cashflows from investing activities 0.88M 1.55M -1.25000M 0.00000M -3.12205M
Dividends paid - - - - -
Change to inventory 0.87M -2.15865M 0.21M -1.60174M -1.48437M
Change to account receivables 0.37M -1.49918M -0.51595M -0.94432M -0.18327M
Sale purchase of stock 9.08M 9.18M 12.86M 20.90M 10.50M
Other cashflows from financing activities 2.23M 2.38M 4.76M 27.47M 5.26M
Change to netincome - 6.67M 17.87M -0.63616M 0.96M
Capital expenditures 0.07M 0.79M 1.46M 7.49M 3.92M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.43M -2.44901M 0.46M 1.34M 0.98M
Stock based compensation 1.04M 1.31M 3.12M 2.69M 1.40M
Other non cash items 3.94M 5.32M 16.43M -1.14734M -0.44401M
Free cash flow -7.50215M -12.45226M -15.42757M -26.93911M -8.90916M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVCN
Avicanna Inc		 -0.005 2.00% 0.24 - - 1.20 880.27 1.25 -4.2593
BHC
Bausch Health Companies Inc		 0.20 3.07% 6.71 - 2.23 0.50 18.74 2.56 9.13
CURA
Curaleaf Holdings Inc.		 0.03 2.52% 1.22 - 138.89 1.62 1.66 1.73 10.18
TLRY
Tilray Inc		 0.02 3.39% 0.61 - 1000.00 2.17 0.36 1.69 -2.299
CRON
Cronos Group Inc		 0.24 9.38% 2.80 - - 10.18 0.70 0.02 -1.9458

Reports Covered

Stock Research & News

View All

Profile

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. It also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, the company operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, and educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens, as well as collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Avicanna Inc

480 University Avenue, Toronto, ON, Canada, M5G 1V2

Key Executives

Name Title Year Born
Mr. Aras Azadian B.Econ, Mba Co-Founder, CEO & Director NA
Dr. Frantz Le Devedec Exec. VP of R&D NA
Mr. Roland Alvarez SVP of Technical Operations NA
Ms. Ivana Maric Exec. VP of Marketing NA
Dr. Carlos Enrique Maldonado Muete SVP of Clinical Devel. NA
Ms. Caitlin Johnston Sr. VP of Strategic Partnerships & Patient Access NA
Mr. Phillip Cardella C.A., CPA Chief Financial Officer NA
Ms. Ivana Maric Executive Vice President of Marketing NA
Mr. Stephen Kim Chief Legal Officer & General Counsel of Avicanna USA Inc. NA
Dr. Karolina Urban Executive Vice President of Scientific & Medical Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.